StratDeck

Two stocks in Healthcare

Eli Lilly and Company vs Regeneron Pharmaceuticals: profit, growth, debt and price compared

Eli Lilly and Company and Regeneron Pharmaceuticals are each stronger on 3 of 7 figures: Eli Lilly and Company on profit margin, sales growth and dividend; Regeneron Pharmaceuticals on debt, price for its expected profit and price trend.

Figures as of 18 November 2026SEC EDGARYahoo Finance
Explore Eli Lilly and Company's storyWhere next ↓

Save both stocks to your watchlist and revisit their latest fundamentals.

Eli Lilly and Company and Regeneron Pharmaceuticals side by side
Eli Lilly and CompanyLLYRegeneron PharmaceuticalsREGN
Net marginStronger: 31.9%28.5%
Revenue growth, past yearStronger: +38.61%+36.27%
Debt to equity122.9%Stronger: 8.1%
Forward P/E27.2×Stronger: 13.3×
Dividend yieldStronger: 0.49%0.39%
AnalystsBuy · 29Buy · 27
From its 200-day average+21.2%Stronger: +24.2%

Share price over the past year

  • Eli Lilly and Company+34.2%
  • Regeneron Pharmaceuticals+30.4%

18 Nov 202518 Nov 2026

Eli Lilly and Company or Regeneron Pharmaceuticals: which is stronger?

  • LLY

    Which is more profitable?

    Eli Lilly and Company keeps more of each sale as profit: 31.9% against 28.5%.

  • LLY

    Which is growing its sales faster?

    Eli Lilly and Company is growing its sales faster: +38.61% over the past year, against +36.27%.

  • REGN

    Which has borrowed less?

    Regeneron Pharmaceuticals has borrowed less: its debt is 8.1% of what its shareholders own, against 122.9% for Eli Lilly and Company.

  • REGN

    Which costs less for the profit it is expected to make?

    Regeneron Pharmaceuticals costs less for the profit it is expected to make: 13.3× its forward earnings, against 27.2×.

  • LLY

    Which pays more in dividends?

    Eli Lilly and Company pays more back in dividends for what a share costs: 0.49% a year, against 0.39%.

  • Which do analysts rate higher?

    Analysts rate both the same: Buy.

  • REGN

    Which is in the stronger price trend?

    Regeneron Pharmaceuticals' price is in the stronger trend: 24.2% above its 200-day average, against 21.2% above.

What each company does

LLYEli Lilly and Company

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.

Reports results on 3 February 2027

REGNRegeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.

Reports results on 28 January 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every US healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.